Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: Does this predict a more severe phenotype?;Coocorrência de mutações nos genes PTPN11 e SOS1 na syndrome de noonan: Este achado prediz um fenótipo mais grave?

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 8, 2010, Pages 717-722

  Brasil, Amanda Salem ^a   Malaquias, Alexsandra C ^a   Wanderley, Luciana Turolla ^a   Kim, Chong Ae ^a   Krieger, José Eduardo ^a   Jorge, Alexander A L ^a   Pereira, Alexandre C ^a   Bertola, Débora Romeo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79951992625     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302010000800009     Document Type: Article

References (32)

1. Nora JJ, Nora AH, Sinha AK, Spangler RD, Lubs HA. The Ullrich- Noonan syndrome (Turner phenotype). Am J Dis Child. 1974;127(1):48-55.
2. Malaquias AC, Ferreira LV, Souza SC, Arnhold IJ, Mendonca BB, Jorge AA. [Noonan syndrome: from phenotype to growth hormone therapy]. Arq Bras Endocrinol Metabol. 2008;52(5):800-8.
3. Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, et al. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet. 2006;79(1):129-35.
4. Musante L, Kehl HG, Majewski F, Meinecke P, Schweiger S, Gillessen- Kaesbach G, et al. Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome. Eur J Hum Genet. 2003;11(2):201-6.
5. Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, et al. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet. 2007;44(12):763-71.
6. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39(8):1007-12.
7. Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet. 2007;39(8):1013-7.
8. Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat. 2009;30(4):695-702.
9. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet. 2007;39(1):75-9.
10. Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, et al. Genotype-phenotype correlations in Noonan syndrome. J Pediatr. 2004;144(3):368-74.
11. Zenker M, Horn D, Wieczorek D, Allanson J, Pauli S, van der Burgt I, et al. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet. 2007;44(10):651-6.
12. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. 2010;1(1):2-26.
13. Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S, Lepri F, et al. Heterozygous Germline Mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet. 2010;87(2):250-7.
14. Brasil AS, Pereira AC, Wanderley LT, Kim CA, Malaquias AC, Jorge AA, et al. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan- like syndromes. Genet Test Mol Biomarkers. 2010;14(3):425-32.
15. Ekvall S, Hagenäs L, Annerén G, Bondeson M. Identification of co-occurring SHOC2 and PTPN11 mutations in a patient with Noonan syndrome. Eur J Hum Genet. 2010;18(1):90-1.
16. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002;30(17):3894-900.
17. Frazer KA, Pachter L, Poliakov A, Rubin EM, Dubchak I. VISTA: computational tools for comparative genomics. Nucleic Acids Res. 2004;32(Web Server issue):W273-9.
18. Silva EG, Slhessarenko N, Arnhold IJ, Batista MC, Estefan V, Osorio MG, et al. GH values after clonidine stimulation measured by immunofluorometric assay in normal prepubertal children and GH-deficient patients. Horm Res. 2003;59(5):229-33.
19. Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002;70(6):1555-63.
20. Ko JM, Kim JM, Kim GH, Yoo HW. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet. 2008;53(11- 12):999-1006.
21. Bertola DR. Estudo do gene PTPN11 nos pacientes afetados pela síndrome de Noonan. São Paulo: Faculdade de Medicina da Universidade de São Paulo; 2006.
22. Binder G, Neuer K, Ranke MB, Wittekindt NE. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab. 2005;90(9):5377-81.
23. Sarkozy A, Conti E, Seripa D, Digilio MC, Grifone N, Tandoi C, et al. Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. J Med Genet. 2003;40(9):704-8.
24. Denayer E, Devriendt K, de Ravel T, Van Buggenhout G, Smeets E, Francois I, et al. Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations. Genes Chromosomes Cancer. 2010;49(3):242-52.
25. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2007;39(1):70-4.
26. Alfieri P, Cesarini L, Zampino G, Pantaleoni F, Selicorni A, Salerni A, et al. Visual function in Noonan and LEOPARD syndrome. Neuropediatrics. 2008;39(6):335-40.
27. Bertola DR, Pereira AC, Albano LM, De Oliveira PS, Kim CA, Krieger JE. PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype. Genet Test. 2006 Fall;10(3):186-91.
28. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I. Arch Dis Child. 1966;41(219):454-71.
29. Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR. Noonan syndrome: growth and clinical manifestations in 144 cases. Eur J Pediatr. 1988;148(3):220-7.
30. Ferreira LV, Souza SA, Montenegro LR, Arnhold IJ, Pasqualini T, Heinrich JJ, et al. [Phenotype variability in Noonan syndrome patients with and without PTPN11 mutation]. Arq Bras Endocrinol Metabol. 2007;51(3):450-6.
31. Bertola DR, Pereira AC, Passetti F, de Oliveira PS, Messiaen L, Gelb BD, et al. Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. Am J Med Genet A. 2005;136(3):242-5.
32. Thiel C, Wilken M, Zenker M, Sticht H, Fahsold R, Gusek-Schneider GC, et al. Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome. Am J Med Genet A. 2009;149A(6):1263-7.